CASE 4-31336P1



paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

David E Wildman

Type or print name

July 5, 2001

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GROUP ART UNIT: 1644

CROWL ET AL.

EXAMINER: P. NOLAN

APPLICATION NO: 09/522,699

FILED: MARCH 10, 2000

JUL 1 2 2001

RECEIVED

FOR: ARTHRITIS-ASSOCIATED PROTEIN

TECH CENTER 1600/2900

Assistant Commissioner for Patents

Washington, D.C. 20231

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING INCLUDING STATEMENT OF VERIFICATION

Sir:

Applicants hereby provide a Substitute Paper and Computer Readable Form of the Sequence Listing. The undersigned states that the Substitute Paper Copy and the Substitute Computer Readable Form of the Sequence Listing include no new matter. The undersigned further states that the Substitute Paper Copy and the Substitute Computer Readable Form, submitted in accordance with 37 CFR §1.825, are the same. Support for the amendment to the Sequence Listing is found on page 27, line 27.

Respectfully submitted,

Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027

(908) 522-6946 Date: July 5, 2001 David E. Wildman Attorney for Applicants

Reg. No. 40,226

